Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 13/20 | 0.74 |
| ▸ | EGFR | P00533 | 4/20 | 0.69 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.69 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.69 |
| ▸ | AURKA | O14965 | 2/20 | 0.69 |
| ▸ | RET | P07949 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2747187 | 0.93 | KDR (0.71) | KDREGFRMAPK14AURKBAURKA | |
| SCHEMBL2747980 | 0.91 | EGFR (0.68) | KDREGFRMAPK14 | |
| SCHEMBL2746015 | 0.89 | KDR (0.62) | KDREGFRMAPK14AURKBAURKA | |
| SCHEMBL2746962 | 0.87 | KDR (0.62) | KDREGFRMAPK14RET | |
| SCHEMBL5753165 | 0.86 | KDR (0.58) | KDREGFRMAPK14AURKBAURKA | |
| SCHEMBL2747392 | 0.85 | KDR (0.69) | KDREGFRMAPK14AURKBAURKA | |
| SCHEMBL4549037 | 0.85 | KDR (0.69) | KDREGFRMAPK14AURKBAURKA | |
| Hydrochloric Acid SCHEMBL8310307 | 0.84 | KDR (0.80) | KDREGFRMAPK14AURKBAURKA | |
| SCHEMBL4821285 | 0.84 | BRAF (0.71) | KDREGFRMAPK14 | |
| SCHEMBL8933899 | 0.83 | AURKB (0.94) | KDREGFRMAPK14AURKBAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178557-B2 | Compounds and methods of use | AMGEN INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178557-B2 | Compounds and methods of use | AMGEN INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178557-B2 | Compounds and methods of use | AMGEN INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20090176774-A1 | Compounds and methods of use | AMGEN INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090176774-A1 | Compounds and methods of use | AMGEN INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090176774-A1 | Compounds and methods of use | AMGEN INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-7435823-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-7435823-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-7435823-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-10-14 | — | — | US | disclosed |
| EP-1720836-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO [D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2006-11-15 | — | — | EP | disclosed |
| US-20060241115-A1 | Compounds and methods of use | AMGEN INC. | 2006-10-26 | — | — | US | disclosed |
| EP-1713484-A2 | COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005082859-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2005-09-09 | — | — | WO | disclosed |
| WO-2005070891-A2 | COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241115-A1 | Compounds and methods of use | HGF, HGFAC, MET | KDR 354/4885EGFR 129/4885MAPK14 1944/4885 |
| US-20090176774-A1 | Compounds and methods of use | HGF, HGFAC, MET | KDR 354/4885EGFR 129/4885MAPK14 1944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.